Blindness is one of the most severe injuries alleged in connection with GLP-1 drugs, including Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Trulicity, Saxenda, and Victoza. A growing number of patients report sudden vision loss, often diagnosed as Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).
Because NAION can cause permanent, irreversible blindness, these claims are treated as a separate, high-severity injury category in GLP-1 litigation and are now handled in their own federal MDL.
What Is NAION?
NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) is a condition caused by reduced blood flow to the optic nerve.
Key characteristics:
- sudden, painless vision loss
- often occurs upon waking
- commonly affects one eye
- damage is frequently permanent
- no proven treatment to restore lost vision
NAION is considered a medical emergency.
Vision Loss Reported After GLP-1 Drug Use
Reported symptoms include:
- sudden blindness in one eye
- partial vision loss or dark spots
- blurred or dim vision
- loss of peripheral vision
- permanent visual field defects
Many patients report no prior warning signs.
How GLP-1 Drugs May Contribute to NAION
Medical experts are evaluating several mechanisms:
A. Blood Pressure & Nocturnal Hypotension
GLP-1 drugs may lower blood pressure, especially overnight — a known NAION risk factor.
B. Dehydration & Volume Depletion
Vomiting and reduced fluid intake can decrease optic nerve perfusion.
C. Rapid Metabolic Changes
Rapid weight loss and vascular changes may increase ischemic vulnerability.
Who Is at Higher Risk?
Risk factors include:
- diabetes
- hypertension
- sleep apnea
- cardiovascular disease
- smoking history
- age 40+
- “crowded” optic nerve anatomy
Many GLP-1 users fall into multiple overlapping risk categories.
Why Blindness Claims Are Treated Separately
Vision loss cases differ because:
- blindness is often permanent
- damages are lifelong
- causation analysis is ophthalmologic
- expert testimony differs from GI cases
As a result, NAION cases are not grouped with gastroparesis or GI MDLs.
➡️ MDL overview: MDL
Evidence Used in NAION Lawsuits
Strong claims often include:
- ophthalmology or neuro-ophthalmology records
- OCT imaging and fundus photography
- visual field testing
- ER or urgent ophthalmology visits
- documented sudden onset
- GLP-1 prescription history
Who May Qualify for a Blindness Claim Review
You may qualify if:
- you used a GLP-1 drug, AND
- you experienced sudden vision loss, AND
- you were diagnosed with NAION or optic nerve ischemia, AND
- vision did not fully recover
➡️ Start here: File a Claim
Related Information
NAION-related blindness is one of the most severe alleged GLP-1 drug injuries. Because vision loss is often permanent, these claims are evaluated separately and handled in a distinct federal MDL. Early medical and legal review is critical.
➡️ Start your review: File a Claim